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REGULAR ARTICLE

A phase 1 trial evaluating thioridazine in combination with cytarabine in
patients with acute myeloid leukemia
Lili Aslostovar,1,2,* Allison L. Boyd,1,* Mohammed Almakadi,1-3,* Tony J. Collins,1 Darryl P. Leong,5 Rommel G. Tirona,6 Richard B. Kim,6
Jim A. Julian,7 Anargyros Xenocostas,8 Brian Leber,9 Mark N. Levine,7 Ronan Foley,4 and Mickie Bhatia1,2

Key Points

• Intermediate-dose
cytarabine can be
safely combined with
TDZ at 50 mg every
6 hours in older
patients with relapsed
or refractory AML.
• A 5-day monotherapy
with TDZ led to
reduced blast counts in
5 out of 11 patients and
was associated with
patient-specific DRD2
level.

We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor
D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine. Thirteen
patients 55 years and older with relapsed or refractory acute myeloid leukemia (AML)
were enrolled. Oral TDZ was administered at 3 dose levels: 25 mg (n = 6), 50 mg (n = 4), or
100 mg (n = 3) every 6 hours for 21 days. Intermediate-dose cytarabine was administered on days 6 to 10. Dose-limiting toxicities (DLTs) included grade 3 QTc interval
prolongation in 1 patient at 25 mg TDZ and neurological events in 2 patients at 100 mg TDZ
(gait disturbance, depressed consciousness, and dizziness). At the 50-mg TDZ dose, the
sum of circulating DRD2 antagonist levels approached a concentration of 10 mM, a level
noted to be selectively active against human AML in vitro. Eleven of 13 patients
completed a 5-day lead-in with TDZ, of which 6 received TDZ with hydroxyurea and 5
received TDZ alone. During this period, 8 patients demonstrated a 19% to 55% reduction
in blast levels, whereas 3 patients displayed progressive disease. The extent of blast
reduction during this 5-day interval was associated with the expression of the putative
TDZ target receptor DRD2 on leukemic cells. These preliminary results suggest that DRD2
represents a potential therapeutic target for AML disease. Future studies are required
to corroborate these observations, including the use of modiﬁed DRD2 antagonists with
improved tolerability in AML patients. This trial was registered at www.clinicaltrials.gov
as #NCT02096289.

Introduction
Therapeutic options for older patients with acute myeloid leukemia (AML) remain limited because
intensified chemotherapies do not improve survival and are poorly tolerated due to age-related
comorbidities.1-3 Furthermore, older patients with relapsed or refractory disease have even fewer
effective treatment options, resulting in complete remission rates of 16% to 21% and median survival of
6 to 9 months.3-5 These poor outcomes highlight the need to evaluate novel therapeutic strategies in
older AML patients, especially those with relapsed or refractory disease.
In 2012, thioridazine (TDZ), a dopamine receptor D2 (DRD2) antagonist, was identified to harbor
potent antileukemic properties in a large-scale chemical screen investigating drugs that alter
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cancer stem cell behavior.6 Preclinical studies with TDZ led to a
marked suppression of leukemic clonogenicity and leukemia
initiation capacity.6 Moreover, in vitro combination of TDZ with the
standard chemotherapy agent cytarabine resulted in an even more
dramatic suppression of leukemic clonogenicity compared with
TDZ alone, highlighting a potentially synergistic effect between
TDZ and cytarabine.6 Importantly, healthy primitive cell output was
not affected after exposure to TDZ at optimal concentrations in
vitro, indicating TDZ’s selectivity to suppress leukemic vs
healthy hematopoietic functions.6

Methods
Patient population
Study patients were 55 years of age or older with relapsed or
refractory AML or high-risk myelodysplastic syndrome who
progressed to AML after hypomethylator therapy. Relapsed
AML eligibility was defined by the presence of $5% leukemic
marrow blasts after 3 months from receiving up to 3 prior
induction regimens. Refractory disease was defined by the
presence of $5% leukemic marrow blasts in patients failing to
achieve a complete remission (CR) or complete remission with
incomplete count recovery (CRi) following not .1 prior induction
regimen. Exclusion criteria included: (i) concomitant use of any
other standard or other investigational anti-leukemic therapies; (ii)
.3 prior lines of chemotherapy for AML; (iii) chemotherapy within
the previous 4 weeks, except for hydroxyurea; (iv) impaired renal
function (estimated glomerular filtration rate ,60 mL/min/1.73 m2)
or abnormal liver function (serum bilirubin .1.53 upper limit
of normal; aspartate transaminase, alanine transaminase, and
alkaline phosphatase .2.53 upper limit of normal); (v) acute or
chronic graft versus host disease; or (vi) on-going uncontrolled
systemic infection. Other specific exclusion criteria included a left
ventricular ejection fraction ,45%, uncontrolled cardiac arrhythmias, diagnosis of prolonged QTc interval at $470 ms for men and
$480 ms for women, or presence of conditions or medications
that prolong the QT interval, known severe hypotensive or hypertensive heart disease.
All patients provided written informed consent, and the trial
protocol was approved by the institutional research ethics
board and Health Canada. The trial was conducted at a single
institution, Hamilton Health Sciences/Juravinski Hospital and
Cancer Centre in Hamilton Ontario. Patients were registered centrally by the Ontario Clinical Oncology Group in
Hamilton Ontario, who was responsible for data management
and adverse event reporting.
1936
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Trial design was a traditional 313 dose escalation phase 1 study12 with
3 dose levels of oral TDZ: 25 mg every 6 hours (dose level/cohort I),
50 mg every 6 hours (dose level/cohort II), and 100 mg every 6 hours
(dose level/cohort III). TDZ was administered for 21 consecutive
days spanning days 1 to 22, and cytarabine was administered at an
intermediate dose (1 g/m2)11 for 5 consecutive days, on days 6 to 10
of the trial. Hydroxyurea was considered optional and was permitted
in the first 5 days of the study, prior to the planned administration of
cytarabine (Figure 1A).

Toxicity evaluation
Toxicity criteria were assessed according to NCI-CTCAE version 4.03.
Dose-limiting toxicity (DLT) was defined as the presence of any toxicity
that was possibly, probably, or definitely related to TDZ, including
$grade 2 neurosensory toxicity-vision, $grade 3 gastrointestinal
toxicity, $grade 3 neurosensory toxicity, $grade 2 renal toxicity,
$grade 2 hepatic toxicity, $grade 2 pulmonary toxicity, $grade 2
neurological toxicity (other than neurosensory toxicity), and $grade 2
cardiac toxicity. A 12-lead electrocardiogram (ECG) was performed
daily. QTc prolongation to .500 ms on at least 2 separate recordings
was considered a DLT (grade 3 as per the NCI-CTCAE version 4.03). A
second ECG was completed within 1 hour from the initial ECG showing
QTc prolongation. If a patient experienced a DLT, the study drug was
permanently discontinued. Drugs known to prolong the QTc, including
specific anti-emetics and anti-fungal agents, were not permitted.

Response evaluation
Bone marrow (20 mL) and peripheral blood (50 mL) specimens
were collected prior to the start of TDZ treatment (day 1), after
treatment with TDZ as a monotherapy and prior to the start of
cytarabine (day 5), on the last day of TDZ treatment (day 22) and on
the last day of the trial (day 36), which was 14 days after the last
dose of TDZ and 26 days after the last cytarabine dose. Previously
defined criteria for complete remission, complete remission with
incomplete count recovery, partial remission, treatment failure, or
not evaluable were used to evaluate leukemic response.3

Pharmacokinetic analysis
Plasma trough concentration of TDZ and its 4 metabolites,13
including TDZ 2-sulfoxide (mesoridazine), thioridazine 2-sulfone
(sulforidazine), thioridazine 5-sulfoxide, and N-desmethyl-thioridazine
(northioridazine), were measured in samples collected on days 1
(prior to the first dose and ;5 hours after the first dose of TDZ) as
well as days 5, 8, 10, 17, 22, 29, and 36. Plasma concentrations of
TDZ and metabolites were determined using liquid chromatographytandem mass spectrometry. Briefly, plasma was spiked with internal
standard (d3-thioridazine; Toronto Research Chemicals) and proteins precipitated by addition of acetonitrile. Solutes were separated
from the resulting plasma extracts by reverse-phase chromatography
(Hypersil Gold C18 column 3 3 50 mm, 5 mm; ThermoFisher
Scientific; Agilent 1100 chromatograph) using gradient elution with
0.1% formic acid in water and acetonitrile. Compounds were
detected after electrospray ionization and detection in positive mode
on a triple quadrupole mass spectrometer (Thermo Vantage) with
multiple reaction monitoring (TDZ m/z 371.2 → 126.2, d3-TDZ m/z
374.2 → 129.2, Northioridazine m/z 357.1 → 112.2, mesoridazine
and 5-sulfoxide m/z 387.2 → 98.1, Sulforidazine m/z 403.2 → 98.1).
The lower limits of quantitation were 3.5 nmol/L for TDZ, 15 nmol/L
14 AUGUST 2018 x VOLUME 2, NUMBER 15
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Based on the prescribed dosage and recognized potential
for adverse effects of TDZ when used as an antipsychotic, 7-10
we designed a phase 1 clinical trial to evaluate the safety of
oral TDZ at 25 to 100 mg every 6 hours alone, and in combination with intermediate-dose cytarabine (1 g/m 2 )11 in patients
55 years and older with relapsed or refractory AML or advanced stage myelodysplastic syndrome. In addition to the
primary outcome measure of safety, we also investigated
circulating DRD2 antagonist levels in relation to TDZ dose.
Finally, we report preliminary observations that suggest an
association between leukemic blast reduction and the level of
DRD2 expression in AML patient cells during a window of TDZ
monotherapy.

Study design and treatment schema

A

B
29 patients screened

8 did not meet entry criteria
Relapse/Refractory
AML patient

3 patients declined this research study
TDZ (25, 50 or 100 mg, PO q6h)

4 patients chose alternative treatment options
1 patient had allergy to cytarabine

Recovery
13 patients enrolled
D1

Cytarabine, D6-10
D5 (1g/m2, IV daily)

D22

D36
2 patients experienced DLTs in the
first 5 days with thioridazine alone

1 patient experienced DLTs during
the thioridazine and cytarabine combination
1 patient left the study
1 death due to disease progression
8 patients received thioridazine plus cytarabine

Figure 1. Study design. (A) Patients received TDZ daily at 3 dose levels including 25 mg every 6 hours (dose level I), 50 mg every 6 hours (dose level II), and 100 mg every
6 hours (dose level III) for 21 consecutive days, spanning days 1 to 22 of the study. Intermediate-dose cytarabine at 1 g/m2 was administered as a 2-hour infusion for 5
consecutive days between days 6 and 10 of the study. (B) Summary of screened and enrolled patients. PO, orally.

for mesoridazine, 7 nmol/L for 5-sulfoxide, 0.2 nmol/L for northioridazine, and 7.5 nmol/L for sulforidazine.

Pharmacogenetic analysis
Genomic DNA was isolated from blood sample preparations with the
Gentra Puregene extraction kit (Qiagen) and quantified by Quant-iT
PicoGreen double-stranded DNA (Invitrogen). CYP2D6 genotyping was
performed by TaqMan Drug Metabolism Genotyping and Copy Number
Assays (Applied Biosystems), using a 7500 Real-time polymerase chain
reaction system (Applied Biosystems). The following inactive or reduced
function alleles were analyzed: CYP2D6*4 (g.1846G.A;
rs3892097), CYP2D6*3 (g.2549A.del; rs1057910), CYP2D6*9
(g.2613_2615delAGA; rs5030656), CYP2D6*10 (g.100C.T;
rs1065852), and CYP2D6*41 (g.2988G.A; rs28371725). CYP2D6
(Hs04502391_cn) copy number variation, deletion, or multiplications
of the gene were also assessed.
Based on CYP2D6 genotypes, patients were categorized into the
following phenotypes14: poor metabolizers if carrying 2 inactive
alleles; intermediate metabolizers if carrying 2 decreased function
alleles or 1 active/decreased function allele and 1 inactive allele;
extensive metabolizers if they were carrying 2 wild-type alleles; or
ultrarapid metabolizers if carrying a gene duplication in the absence
of inactive or decreased function alleles.

Primary patient sample processing and
flow cytometry
Mononuclear cells (MNCs) were prepared from clinical bone marrow
and peripheral blood samples at baseline by density gradient
centrifugation (Ficoll-Paque Premium, GE Healthcare), followed by
red blood cell lysis using ammonium chloride solution (Stemcell
Technologies).
Cell surface immunophenotyping for DRD2 was performed using
mouse anti-human DRD2 (clone B-10; Santa Cruz Biotech) with
14 AUGUST 2018 x VOLUME 2, NUMBER 15

donkey anti-mouse immunoglobulin G Alexa-Fluor-647 (Life Technologies) as the secondary antibody. Samples were blocked with donkey
serum (Jackson ImmunoResearch Laboratories) plus human FC block
(eBioscience). Fluorescence-minus-one controls were used for
optimized gating. 7-Aminoactinomycin D (Beckman Coulter) was
used for live/dead cell discrimination.

In vitro drug treatment with TDZ
Patient-derived MNCs were exposed to 0.1% dimethyl sulfoxide
control or TDZ at doses ranging from 0.69 mM to 40 mM for
24 hours in vitro, followed by analysis of leukemia cell viability by
7-aminoactinomycin D exclusion using a LSRII flow cytometer (BD).
Culture conditions included Stemspan medium (Stemcell Technologies) supplemented with 100 ng/mL stem cell factor, 100 ng/mL
FMS-related tyrosine kinase 3 ligand, and 20 ng/mL thrombopoietin
(all sourced from R&D Systems).

Statistical analysis
Continuous data were described using means and 95% confidence
intervals (CI), and dichotomous data were summarized as percentages. Group comparisons were performed using 2-tailed Student
t test for continuous measures and Fisher’s exact test for
dichotomous outcomes. Square root transformation was used prior
to statistical analysis when data failed to meet parametric requirements and data set included values equal to 0. Prism software
(version 5.0a; GraphPad) was used for all statistical analyses.
P # .05 was considered to be statistically significant.

Results
Trial overview
Between July 2014 and September 2016, a total of 29 AML
patients were screened. Of these, 13 AML patients aged 55 years
or older with relapsed or refractory disease (n 5 9) or AML with
THIORIDAZINE IN HUMAN AML
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11 patients completed monotherapy with thioridazine

Safety profile
Major toxicities are summarized in Table 2. Consistent with previous reports, QTc prolongation was the most frequent adverse
event.7,10,15-17 As would be predicted for TDZ effects from previous
clinical studies,18 more frequent QTc prolongation events were noted
with TDZ dose escalation. Although limited to a small number of
patients, the most dramatic episodes of QTc elongation were
observed in patients with the highest QTc interval at baseline.
Specifically, patient 3 had a grade 3 QTc elongation and patient
9 experienced the highest frequency of grade 2 QTc prolongations.
Both patients exhibited baseline QTc levels that exceeded 440 ms,19
greater than all other trial patients (Table 3). From a baseline QTc of
445 ms, patient 3 developed severe (grade 3) QTc prolongation to
553 ms on day 7 of TDZ treatment, coinciding with the second day
of cytarabine treatment. This was considered a DLT, leading to
permanent discontinuation of TDZ for this patient. However, it is
noteworthy that following TDZ discontinuation, patient 3 continued to
show significant QTc prolongation (supplemental Figure 1). Moreover, after plasma concentrations of TDZ and TDZ 5-sulfoxide
(the metabolite associated with cardiotoxicity19-22) were reduced to
undetectable levels, frequent QTc prolongation events continued to be
noted on serial ECGs (supplemental Figure 1). These QTc changes in
patient 3 were not associated with fluctuations in magnesium or
potassium levels. Other instances of QTc prolongation included grade
2 QTc prolongations (between 481 and 500 ms, NCI-CTCAE version
4.03) in patients 7 and 9 in dose level II, as well as patient 11 in dose
level III. No other cardiac-related DLTs were reported.
In addition to cardiac adverse events, neurological DLTs were noted
in 2 patients at dose level III (100 mg every 6 hours). Patient 12
experienced grade 3 depressed level of consciousness and patient
1938
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Table 1. Patient characteristics at baseline
Dose level I
(n 5 6)

Dose level II
(n 5 4)

Dose level III
(n 5 3)

66 (58-75)

71.5 (67-79)

71 (58-75)

4:2

1:3

2:1

0

2

0

2

1

4

4

1

2

0

0

0

Relapsed/refractory AML

4

3

2

AML-MRC

2

1

1

Favorable

0

0

0

intermediate

4

2

2

Adverse/high

2

2

1

#3

5

1

0

$4

1

3

2

NA

0

0

1

Median age (range), y
Sex, male:female
ECOG performance, n

Diagnosis, n

Cytogenetics risk group, n

No. of prior chemotherapy
regimens

% BM blast at baseline,
mean 6 SEM
ABC 3 109/L at baseline,
mean 6 SEM

60.3 6 10.0
9.2 6 3.9

71 6 10.6
29.4 6 26.7

50 6 14.9
4.0 6 3.9

ABC, absolute blast count; BM, bone marrow; ECOG, Eastern Cooperative Oncology
Group; SEM, standard error of the mean.

13 experienced grade 2 dizziness and gait disturbance (Table 2).
Other nonhematologic grade $2 adverse events that were not doselimiting included fatigue (n 5 1) and urinary incontinence (n 5 1)
(Table 2). Frequent grade 3 or greater adverse events predominantly
included cytarabine-related myelosuppression and associated complications. These adverse events were observed across all 3 cohorts,
independent of the dose of TDZ, and included anemia, reduced
platelet, neutrophil, and leukocyte counts. Patients were managed with standardized transfusions and administration of antimicrobial agents according to the institutional standard of care. There were
4 episodes of grade $3 sepsis in patients 8 and 11 to 13. All 4 cases
of sepsis were considered unrelated to TDZ. There was 1 on-study
death (patient 12), which was associated with disease progression.
Based on the dose-related neurological DLTs observed in dose level
III, we concluded that oral TDZ at 50 mg every 6 hours in combination
with intermediate-dose cytarabine was safe and feasible in older
patients with relapsed or refractory AML.

Pharmacokinetics and pharmacogenetics
Pharmacokinetic analyses were performed to determine whether
a safe dose of TDZ would achieve the target plasma concentrations of TDZ (10 mM) that we previously reported to display
antileukemic activity in vitro.6 Blood samples were collected to
measure plasma trough concentration of TDZ and its 4 metabolites on days 1, 5, 8, 10, 17, 22, 29, and 36. As previously reported,
the concentration of TDZ and metabolites accumulated upon
repeated dosing23 and steady-state plasma TDZ was achieved
14 AUGUST 2018 x VOLUME 2, NUMBER 15
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myelodysplastic-related changes (AML-MRC; n 5 4) met the
eligibility criteria and were enrolled (Figure 1B). Baseline patient
characteristics are summarized in Table 1. Patient 3 in dose level I
experienced grade 3 QTc interval prolongation to 535 ms on day
7. This DLT led to discontinuation of TDZ for this patient, and the
patient was removed from the study after completion of cytarabine
on day 10. As a result of this DLT, 3 additional patients were
enrolled in dose level I according to the study protocol.12 At dose
level II, patient 8 left the study on day 9 on personal request. For
patient 11 in dose level III, the dose of TDZ was temporarily
deescalated from 100 mg every 6 hours to 50 mg every 6 hours on
day 10 after this patient experienced grade 2 QTc prolongation
events. This patient later developed severe sepsis on day 16,
which was considered unrelated to TDZ but led to permanent
discontinuation of TDZ because the patient required intensive
care. Patient 12 at dose level III experienced a grade 3 depressed
level of consciousness on day 3. Patient 13 at dose level III
suffered from grade 2 dizziness and gait disturbance on day 3.
These neurological symptoms were considered DLTs and subsequently defined the maximum tolerated dose of 50 mg TDZ
every 6 hours in this patient population. Thus, in total, 2 patients
(15%) did not complete the study; 3 participants (23%) developed DLTs, and 8 patients (61%) received the treatment
regimen that included TDZ treatment in combination with
intermediate-dose cytarabine (Figure 1B). Among these 8, patient
11 received cytarabine on days 6 to 10 and TDZ up to day 16. The
remaining 7 patients received the full course of TDZ therapy
between days 1 to 22 in addition to cytarabine on days 6 to 10.

Table 2. Adverse events grade ‡2 possibly related to TDZ
Dose level I (n 5 6)

Dose level II (n 5 4)

Dose level III (n 5 3)

Grade

Frequency per
cohort, n (%)

Frequency of
occurrence

Frequency per
cohort, n (%)

Frequency of
occurrence

Frequency per
cohort, n (%)

Frequency of
occurrence

Total frequency
of occurrence

Fatigue

2

1 (16)

1

0 (0)

0

0 (0)

0

1

Urinary incontinence

2

0 (0)

0

1 (25)

1

0 (0)

0

1

Adverse event
General

Neurological
2

0 (0)

0

0 (0)

0

1 (33)

1

1

Dizziness

2

0 (0)

0

0 (0)

0

1 (33)

1

1

Depressed level of
consciousness

3

0 (0)

0

0 (0)

0

1 (33)

1

1

QTc interval prolongation
(481-500 ms)

2

0 (0)

0

2 (50)

7

1 (33)

2

9

QTc Interval prolongation
($501 ms on at least 2
separate ECGs)

3

1 (16)

1

0 (0)

0

0 (0)

0

1

Cardiovascular

approximately by day 5, prior to the administration of cytarabine
(Figure 2A; supplemental Figure 2). At dose level III, only patient 11
achieved steady-state plasma TDZ levels. However, for this patient,
TDZ was deescalated to 50 mg every 6 hours on day 10 after 2
grade 2 QTc prolongation events. On day 16, TDZ was completely
discontinued due to the development of sepsis, which was
considered unrelated to TDZ. Steady-state plasma TDZ level
was not achieved for patients 12 and 13 because TDZ was
discontinued early on days 4 and 2, respectively.
Steady-state plasma TDZ concentrations were dose dependent.
However, the target concentration of 10 mM TDZ was not achieved in
any of the cohorts (Figure 2B). In cohorts II and III, the sum of TDZ
and its 2 metabolites exhibiting DRD2 antagonism (2-sulfoxide and
2-sulfone24-27) approached 10 mM (Figure 2C). Detectable levels of
TDZ and its 2 principal metabolites, including 2-sulfoxide and
5-sulfoxide,28 were sustained for ;1 week after the last dose of TDZ
(day 29) (Figure 2A). By day 36, TDZ and metabolites were no longer
detectable in plasma (Figure 2A). TDZ is metabolized by Cytochrome
P450 2D6 enzyme (CYP2D6), and CYP2D6 polymorphism has been
associated with variability in drug metabolism.29-31 CYP2D6 genotyping of our patients indicated intermediate and extensive metabolizing phenotypes (Figure 2D), which may contribute to interpatient
heterogeneity in plasma drug concentrations.18,23,28 As previously
reported, patients with predicted extensive metabolizer phenotypes
exhibited lower plasma concentrations for TDZ and metabolites
compared with intermediate metabolizers within the same TDZ dose
level31,32 (Figure 2D). We did not observe any cases of poor or
ultrarapid metabolizers in this cohort, consistent with their rare
occurrence in the wider population.14,33

Responses to treatment
To evaluate the effect of TDZ against human AML disease, the trial
incorporated a lead-in phase with TDZ administration alone (days
1-5) prior to the combination with cytarabine (days 6-10). Bone
marrow and peripheral blood samples were collected to evaluate
effects on day 5 in response to TDZ alone, on day 22 after
termination of TDZ (12 days after the end of cytarabine), and on day
14 AUGUST 2018 x VOLUME 2, NUMBER 15

36 for end point response assessment (Figure 1A). Day 36
coincided with day 14 after the last dose of TDZ and 26 days after
the last dose of cytarabine. Patient responses on day 36 are
summarized in Table 3. Of the 13 patients, patients 3, 8, 12, and 13
received less than one-third of the scheduled dose of TDZ, and
patients 8 and 12 missed the cytarabine treatment and were
therefore excluded from this analysis (Table 3). Of the remaining
9 evaluable patients, 1 patient (patient 2) achieved partial remission as defined by a .50% reduction of bone marrow blasts
relative to pretreatment levels.3 Patient 7 showed no response
in the bone marrow but displayed a 66% reduction of peripheral
blast levels. The 7 remaining patients showed resistant disease
patterns on day 36.
Assessment of patient outcomes after the 5-day lead-in period with
TDZ administration alone revealed a reduction of peripheral
leukemic burden ranging from 19% to 55%, in 8 of the 11 patients
(72%) who completed the 5-day portion of the study (Figure 3A).
These outcomes appear modest based on established clinical
thresholds,3 yet noteworthy given the brief exposure period to TDZ.
Moreover, the effects of TDZ as a monotherapy was further
highlighted when the 5-day blast fluctuations were compared with
the patients’ respective blast trajectories prior to the start of the trial
and in the absence of TDZ (Figure 3A). It is important to note that
hydroxyurea was concurrently administered in 6 of the 11 patients
during the 5-day lead-in with TDZ (Figure 3A), as previously
reported in clinical trials where patients present with advanced
disease states.34-36 These included 4 of the 8 patients with partial
responses to TDZ (patients 4, 7, 10, and 11), as well as 2 of the
3 patients with no response to TDZ, which continued to show
progressive disease trends despite the use of hydroxyurea (patients
1 and 3). Although it cannot be ruled out that the concurrent use
of hydroxyurea may have contributed to the cytoreduction during
the 5-day lead-in with TDZ and may therefore confound the definitive assessment of DRD antagonism in 4 patients, blast level
suppression observed after TDZ monotherapy cannot be attributed
to hydroxyurea in at least 4 other patients that did not receive
hydroxyurea treatment. Moreover, the overall patterns of blast
THIORIDAZINE IN HUMAN AML
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Gait disturbance

0.2
NA
ELN, European LeukemiaNet; EPI, European Prognostic Index; ID, identification; NE, nonevaluable.
*Day 22 values indicated because day 36 value was unavailable.
†Value reported in a follow-up later than day 36.

NE

NE
56

0
432
Poor/ELN

Intermediate/EPI score

AML-MRC diagnosis

Relapse

Complex karyotype

46,XY/normal

NE
13

12
424
Intermediate/EPI score
46,XY, der(22) t(1;22)(q11;p11.2)

Relapse

NE
Early/DLT

Early/DLT

12

22

69†
73
Normal
11

16.6

74

34
45
0

2.5
Relapse
46,XY/normal

455
AML-MRC diagnosis
46,XY/normal

419

Intermediate/EPI score
Relapse

High/EPI score

411

High/ EPI score

Intermediate/ELN

0

Normal
10

1.2

Normal
9

64

NE
5.4

438

407.3

Intermediate/ELN
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71*
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94
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46,XX, del(5)(q13q33)/FLT3-D8351
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7
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AML-MRC diagnosis
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6
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78*
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1.8
1
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Normal
5
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24.8
409.3

419
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AML-MRC diagnosis
46,XY, del(9)(q13q22)/FLT3-ITD1

46,XX/normal

Early/disease progression
4

61

7

NE
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445
3

0
407

NE
Intermediate/refractory score
Relapse-2
46,XX,t(8;14)(p11.2;q32.1)

89

69

Early/DLT

46

54
11.6
436.6

Normal
2

High/refractory score
Normal
1

Intermediate/EPI score

0.4
46,XY/normal

14.6
Refractory

Relapse

46,XY,del(7)(q11.2)

Day 36 BM
blast, %
Day 1 BM
blast, %
Day 36 PB
blast count, 3 109/L
Day 1 PB
blast count, 3 109/L
Baseline
QTc
Prognosis/classification
Disease stage
CG/molecular
Termination/reason

Table 3. Patient details and tumor response on day 36

Patient ID
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After this 5-day interval, peripheral blast levels continued to
decline with the addition of cytarabine (days 6-10), and up to
day 22 when TDZ was stopped (supplemental Figure 3C). Within
the 5-day monotherapy with TDZ, residual neutrophil counts
were not dramatically reduced compared with baseline levels
(Figure 3B). Platelet counts were evaluated among patients who
did not receive transfusions prior to or during the 5-day
monotherapy with TDZ (Figure 3C), and circulating platelet levels
were safely managed according to the institutional standard of care.
These observations suggest that TDZ can be practically coupled with
cytarabine.
TDZ has been historically administered as an antipsychotic drug
whose properties are mediated through DRD2 antagonism.37
Previous in vitro assays using patient AML cells suggested that
DRDs also mediate TDZ’s selective suppression of human AML,
due to a preferential expression pattern in leukemic vs healthy
hematopoietic progenitor cells.6 Specifically, DRD2 protein expression was detected at a maximum of 1% within primitive cell
fractions obtained from multiple independent healthy donor
samples (supplemental Figure 3D). This provided a threshold to
identify preferential DRD2 expression between leukemic and
healthy hematopoietic cells. Based on this benchmark, 9 patients
harbored DRD2 expression (.1%) at baseline, and 8 of these
patients displayed blast reduction after exposure to TDZ. In
contrast, ,1% DRD2 expression at baseline was associated with
lack of a biological response to TDZ (Figure 3D; supplemental
Figure 3E).
Despite not achieving target steady-state plasma TDZ concentrations
of 10 mM TDZ, our results provide signals of clinical efficacy with the
DRD2 antagonist TDZ. Moreover, the association between response
to TDZ and patient-specific DRD2 expression supports the relevance
of DRD-based therapies for a subset of patients with notable DRD2
levels. To determine the extent of patients that may benefit from a
potential DRD-targeted approach, we expanded our analysis to 20
additional AML samples, which revealed that 80% of patients express
robust levels of DRD2 (Figure 3E). These observations form the
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reduction during the 5-day monotherapy was found to be
statistically independent of hydroxyurea (P 5 1.00 by Fisher’s
exact test; supplemental Figure 3A), the coadministration of which
has not always been reported in previously published clinical
studies. To dissociate between the effects of TDZ from hydroxyurea
on blast level reduction in patients given TDZ and hydroxyurea vs
TDZ alone, we opted for controlled in vitro experimental settings
where the antileukemic effects of TDZ could be safely interrogated
as a single agent in the absence of hydroxyurea, using patient
leukemic cells obtained at baseline prior to initiation of the study.
Because the potential contributing effect of hydroxyurea was in
question, we focused on hydroxyurea-treated patients and selected
3 cases that represented the greatest response to TDZ (patient
7, 255% circulating blasts), medium-level response (patient 4,
221% circulating blasts), or no response (patient 1, 1368%
circulating blasts) during the 5-day monotherapy (Figure 3A). When
these 3 patient samples were treated with TDZ in vitro, their relative
sensitivity to TDZ as measured by leukemia cell viability resembled
their respective patterns of clinical response to TDZ monotherapy,
suggesting that the antileukemic effect of TDZ can be reproduced
in the absence of hydroxyurea and is cell-intrinsically regulated
(supplemental Figure 3B).
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Figure 2. Pharmacokinetic analysis. (A) TDZ trough concentrations were measured on days 1, 5, 8, 10, 17, 22, 29, and 36 for each study cohort. Plasma TDZ
concentrations reached a steady state by day 5, and TDZ remained detectable up to day 29. In cohort III, TDZ was discontinued early for patients 12 and 13, and only patient
11 received doses to achieve steady-state plasma TDZ concentrations. This patient received TDZ at dose level III (100 mg every 6 hours) for the first 10 days (solid line), after
which TDZ was deescalated to 50 mg every 6 hours (broken line) up to day 16 and discontinued thereafter. Data for cohorts I and II are displayed as mean 6 standard error
at each assessment point. (B) Plasma TDZ levels at steady state in relation to the target 10 mM concentration (conc.), previously shown to be effective against human AML
in vitro.6 Data are expressed as cohort means and 95% CI. (C) Sum of plasma TDZ and its 2 active metabolites (2-sulfoxide and 2-sulfone) with DRD2 antagonistic effects
in relation to the target concentration of 10 mM. Data are expressed as cohort means and 95% CI. (D) Sum of circulating DRD2 antagonist levels for individual patients
normalized to daily dose of TDZ. Patient variation in plasma DRD2 antagonist level was associated with CYP2D6 genotype and its predicted drug metabolism phenotypes
(difference between group means: 18.22, 95% CI: 4.1 to 32.3; P 5 .01).

foundation for the application of DRD-based targeted therapies for a
substantial proportion of adult AML patients.

Discussion
Current therapeutic options for older AML patients with relapsed or
refractory disease are associated with poor therapeutic responses
and poor survival outcomes.3,38 In patients at second or third
relapse, median overall survival is further reduced to as low as
3 months,3 indicating an urgent need for novel therapies and
targets. In pursuit of novel drug targets against AML disease, we
previously carried out a high throughput chemical screen that led to
the identification of DRD2 antagonist TDZ, a former antipsychotic
drug with newly described selectivity for cancer cells over normal
counterparts.6 In vitro treatment testing of leukemic vs healthy
hematopoietic progenitors with TDZ led to a suppression of
clonogenic growth and leukemic disease initiating capacity in
primitive leukemia cells.6 The readout of these functional assays has
been associated with leukemic blast production in patients,39-43
suggesting a potential therapeutic benefit. In addition to AML,
anticancer effects of TDZ have been reported in a wide range of
cancers, including lymphomas,44 brain tumors,45-47 breast,48 and
ovarian.49,50 This body of clinical evidence related to anticancer
effects of TDZ motivated this phase 1 study, facilitating an initial
step toward evaluating the translational potential of DRD2
antagonism in AML disease.
The primary objective of our clinical trial was to evaluate the safety and
feasibility of oral TDZ at routine therapeutic doses,51 in combination
with intermediate-dose cytarabine in older AML patients with relapsed
or refractory disease. The trial included a 5-day lead-in with TDZ alone,
as well as a combination phase with cytarabine, providing a unique
opportunity to interrogate the effect of TDZ as a monotherapy and
together with cytarabine within a single trial. We found that despite the
presence of poor cytogenetic features that are associated with
adverse therapy responses,3 leukemic burden was reduced in 8 of
14 AUGUST 2018 x VOLUME 2, NUMBER 15

11 patients following the 5-day exposure to TDZ monotherapy
(Figure 3A), and the effects were associated with the level of
DRD2 expression at baseline (Figure 3D). After this 5-day
monotherapy with TDZ, the peripheral leukemic burden continued
to decline with the addition of cytarabine (day 6-10) up to day 22
when TDZ was stopped (supplemental Figure 3C). After day 22, we
noted an increase in blast levels as patients approached the end
point on day 36 (Table 3). These outcomes suggest that DRD
antagonism may be required chronically to sustain durable effects
on AML blast suppression. However, the neuroleptic symptoms and
cardiotoxicity observed here and in previous reports9 precludes
a safe dosing with TDZ for extended periods. Possible modifications include gradual intrapatient dose escalation to improve on
tolerability,46,52 and/or prioritization of younger AML patients to
reduce the risk of cardiotoxicity. This is particularly important,
because the median age of patients in all 3 cohorts was .65, which
is an independent predictor of QTc prolongation.10 More importantly,
chronic regimens may be achievable with alternative formulations of
TDZ that are more readily tolerated.
Our safety study provides preliminary signs of potential clinical
efficacy, despite the inability to achieve plasma TDZ levels that match
concentrations demonstrated to be effective in vitro.6 This suggests
that the in vivo potency of TDZ may not directly correspond to the half
maximal effective concentrations defined using in vitro assays.53 The
biological effects in patients achieved at these modest plasma
concentrations reinforce the therapeutic relevance of DRD2 targeting in human AML disease. In line with our observations here,
previous studies with larger patient cohorts have reported reduced
rates of solid tumor incidence in schizophrenic patients, which has
been proposed to be associated with DRD antagonist treatment.54,55
In the current study, the antileukemic effect of TDZ was observed predominantly in the peripheral blood and did not meet the
established clinical remission criteria for AML. However, these
measurements and outcomes using TDZ alone resemble that of
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Figure 3. Response. (A) Response to a 5-day treatment with TDZ as a monotherapy was monitored at the level of peripheral blood ABC. Response for patients 2 and 9 was
determined by percent bone marrow blast due to a lack of circulating blasts as indicated by the asterisk. Patients 12 and 13 were excluded from this analysis because they did
not complete the 5-day treatment with TDZ. Red curves indicate disease progression based on ABC prior to the start of TDZ treatment. Blue color coding indicates TDZ dose
level. Insets depict percent change in blast counts at day 5 compared with day 1. “1HU” indicates concurrent use of hydroxyurea during the 5-day treatment with TDZ. (B)
Absolute neutrophil counts after exposure to up to 100 mg of TDZ every 6 hours based on data from 11 patients that completed the 5-day monotherapy with TDZ. Data are
expressed as cohort means and 95% CI (mean change from day 1 to day 5: 21.00, 95% CI: 22.7 to 0.7, P 5 .22). (C) Platelet counts after a 5-day treatment with up to 100 mg
of TDZ every 6 hours. Data points include patients that did not receive platelet transfusions within the first 5 days of TDZ, or up to 4 days prior to the start of the trial. Data are expressed
as cohort means and 95% CI (mean change from day 1 to day 5: 223.00, 95% CI: 245.4 to 20.54, P 5 .04). (D) Baseline levels of DRD2 protein expression in MNCs of patients that
showed no blast response vs patients that showed blast reduction after the 5-day treatment with TDZ (difference between group means: 1.20, 95% CI: 0.56 to 1.84; P 5 .002). The
shaded area indicates the upper and lower 99% CI for DRD2 levels in healthy primitive cells as defined in supplemental Figure 3D. (E) DRD2 protein expression in MNCs of 20 AML
patient samples (16 diagnosis and 4 relapse cases) not including on-study patients. The shaded area indicates the upper and lower 99% CI for DRD2 levels in healthy primitive cells
(CD341) as defined in supplemental Figure 3D. Inset depicts a representative flow cytometry plot for DRD2 expression in AML (red histogram), overlayed on the staining control (dotted
histogram).

early generation FLT3 inhibitors in clinical testing that also
reduced leukemia blast levels with greater potency in the
peripheral blood vs the bone marrow.56 Similar to our findings
with TDZ reported here, the preliminary results using FLT3
inhibitors formed the foundation for more informed future clinical
trials and the development of refined versions of the drug.
Subsequent generations of FLT3 inhibitors have evolved into
some of the most promising targeted therapies when combined
with induction chemotherapy,57 with improved outcomes in
patients that express the drug target in a minority of blast cells,57
similar to minor fractions reported for DRD expression in this
cohort.
Future studies are required to corroborate these preliminary
findings in the absence of concurrent hydroxyurea or within
2-armed trials, to more discretely determine the antileukemic
potential of DRD antagonism as a monotherapy. Also, larger patient
cohorts and modified formulations of TDZ that display reduced
neurological and cardiac liability should be considered for future
trials. Such analogs are currently under investigation by our group.
Our study offers a conceptual advancement toward understanding
the biology and vulnerabilities of AML through DRDs and holds
promise for a novel therapeutic target to combat AML disease.
1942
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19. Hartigan-Go K, Bateman DN, Nyberg G, Mårtensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites
in humans. Clin Pharmacol Ther. 1996;60(5):543-553.
20. Hale PW Jr, Poklis A. Thioridazine-5-sulfoxide cardiotoxicity in the isolated, perfused rat heart. Toxicol Lett. 1984;21(1):1-8.
21. Hale PW Jr, Poklis A. Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol Appl
Pharmacol. 1986;86(1):44-55.
22. Gottschalk LA, Dinovo E, Biener R, Nandi BR. Plasma concentrations of thioridazine metabolites and ECG abnormalities. J Pharm Sci. 1978;67(2):
155-157.
23. Ng CH, Crammer JL. Measurement of thioridazine in blood and urine. Br J Clin Pharmacol. 1977;4(2):173-183.

14 AUGUST 2018 x VOLUME 2, NUMBER 15

THIORIDAZINE IN HUMAN AML

1943

Downloaded from http://ashpublications.org/bloodadvances/article-pdf/2/15/1935/881270/advances015677.pdf by guest on 04 July 2022

1.
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